The safety and efficacy of dapagliflozin therapy in combination with insulin in Japanese subjects with T1DM

Trial Identifier: D1695C00001
Sponsor: AstraZeneca
NCTID:: NCT02582814
Start Date: October 2015
Primary Completion Date: June 2017
Study Completion Date: June 2017
Condition: Diabetes: Type 1

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation
Japanese Translation

Trial Locations

Country Location
Japan Aizu Wakamatsu-shi, Japan
Japan Chuo-ku, Japan
Japan Fukuoka-shi, Japan
Japan Fukuyama-shi, Japan
Japan Funabashi-shi, Japan
Japan Hamamatsu-shi, Japan
Japan Hirosaki-shi, Japan
Japan Hiroshima-shi, Japan
Japan Ise-shi, Japan
Japan Kagoshima-shi, Japan
Japan Koriyama-shi, Japan
Japan Kumamoto-shi, Japan
Japan Kunitachi-shi, Japan
Japan Minato-ku, Japan
Japan Nagoya-shi, Japan
Japan Oita-shi, Japan
Japan Otsu-shi, Japan
Japan Oyama-shi, Japan
Japan Sapporo-shi, Japan
Japan Sendai-shi, Japan
Japan Shinjyuku-ku, Japan
Japan Suita-shi, Japan
Japan Tama-shi, Japan
Japan Tsukuba-shi, Japan
Japan Yokohama-shi, Japan